1.Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues.
Hans Christoph DIENER ; Christoph KLEINSCHNITZ
Journal of Stroke 2016;18(2):138-145
Non-vitamin-K oral anticoagulants (NOACs) represent a major advance in the prevention of stroke in patients with atrial fibrillation (AF), offering a similar, if not superior, efficacy and safety profile and several practical advantages over oral vitamin K antagonists (VKAs). The rapid onset of action of the NOACs, their relatively short half-live, and the availability of specific reversal agents may be advantageous when managing acute ischemic strokes, and in the post-stroke, post-transient ischemic attack, and post-intracranial hemorrhage settings. In this review article, we offer practical guidance on the use of NOACs in these settings, focusing on managing the acute event and on initiating or resuming anticoagulation for secondary prevention. We also assess the use of NOACs to prevent stroke and bleeding in patients with AF who have chronic kidney disease, are elderly, or cognitively impaired, and we offer guidance on optimizing the use of NOACs and VKAs in these patient groups in the absence of evidence-based guidelines.
Aged
;
Anticoagulants*
;
Atrial Fibrillation
;
Hemorrhage
;
Humans
;
Ischemic Attack, Transient
;
Renal Insufficiency, Chronic
;
Secondary Prevention
;
Stroke*
;
Vitamin K
3.Establishment of the Heart and Brain Team for Patent Foramen Ovale Closure in Stroke Patients: An Expert Opinion
Jong S. KIM ; Vincent THIJS ; Matias YUDI ; Kazunori TOYODA ; Masayuki SHIOZAWA ; Jin ZENING ; Brian CLAPP ; Bert ALBERS ; Hans-Christoph DIENER
Journal of Stroke 2022;24(3):345-351
The online 2021 Asian-Pacific Heart and Brain Summit was organized to present and discuss experiences within leading Asian-Pacific centers with regard to institutional heart and brain teams managing the diagnosis, treatment, and follow-up of cryptogenic stroke (CS) patients with patent foramen ovale (PFO). This manuscript presents a narrative review of presentations and discussions during the summit meeting. Percutaneous PFO closure is an established therapy for CS patients in whom PFO is considered to be causal. Guidelines and consensus statements emphasize the importance of multidisciplinary clinical decision-making regarding PFO closure with the involvement of several clinical specialties, including neurology, cardiology, and hematology. It is also recommended that the patient be closely involved in this process. The heart and brain team is a collaborative platform that facilitates such a multidisciplinary decision-making process and patient involvement. It also creates opportunities for education and evaluation of the healthcare provided to patients with CS. This review provides insights into the implementation, composition, organization, and operation of a heart and brain team. Methods and metrics are suggested to evaluate the team’s role. We suggest that an efficient heart and brain team can implement guideline-recommended multidisciplinary clinical decision-making with regard to PFO closure in CS patients and play an important role in the management of these patients.
4.Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)
Martin J. O’DONNELL ; Matthew MCQUEEN ; Allan SNIDERMAN ; Guillaume PARE ; Xingyu WANG ; Graeme J. HANKEY ; Sumathy RANGARAJAN ; Siu Lim CHIN ; Purnima RAO-MELACINI ; John FERGUSON ; Denis XAVIER ; Liu LISHENG ; Hongye ZHANG ; Prem PAIS ; Patricio LOPEZ-JARAMILLO ; Albertino DAMASCENO ; Peter LANGHORNE ; Annika ROSENGREN ; Antonio L. DANS ; Ahmed ELSAYED ; Alvaro AVEZUM ; Charles MONDO ; Conor JUDGE ; Hans-Christoph DIENER ; Danuta RYGLEWICZ ; Anna CZLONKOWSKA ; Nana POGOSOVA ; Christian WEIMAR ; Romana IQBAL ; Rafael DIAZ ; Khalid YUSOFF ; Afzalhussein YUSUFALI ; Aytekin OGUZ ; Ernesto PENAHERRERA ; Fernando LANAS ; Okechukwu S. OGAH ; Adesola OGUNNIYI ; Helle K. IVERSEN ; German MALAGA ; Zvonko RUMBOLDT ; Shahram OVEISGHARAN ; Fawaz AL HUSSAIN ; Yongchai NILANONT ; Salim YUSUF ;
Journal of Stroke 2022;24(2):224-235
Background:
and Purpose The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes.
Methods:
Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH).
Results:
Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001).
Conclusions
The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.